ALTEOGEN stock
Price history
−60.77% over the period1 year: from ₩430,000.00 (November 18, 2025) to ₩168,700.00 (November 18, 2026), −60.77%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 18, 2026 | ₩168,700.00 |
| October 30, 2026 | ₩211,500.00 |
| September 30, 2026 | ₩254,500.00 |
| August 31, 2026 | ₩307,500.00 |
| July 31, 2026 | ₩237,307.69 |
| June 30, 2026 | ₩277,692.31 |
| May 29, 2026 | ₩283,846.16 |
| April 30, 2026 | ₩283,461.53 |
| March 31, 2026 | ₩262,692.31 |
| February 27, 2026 | ₩313,461.53 |
| January 30, 2026 | ₩317,692.31 |
| December 30, 2025 | ₩345,769.22 |
| November 28, 2025 | ₩410,000.00 |
| November 18, 2025 | ₩430,000.00 |
At a glance
The company
Develops long-acting biobetters, antibody-drug conjugates, and antibody biosimilars for cancer, hemophilia and other diseases
Latest results
Quarter to September 30, 2026 · EPS ₩691.68 (estimate ₩607.73)
Next event
TickerLandia's take on ALTEOGEN
- Pricier than similar companies: trailing 12-month P/E 97 vs 47 (+109%) in a group of 8.
- Strong point: Profitability (84/100 in its group). Weak point: Market momentum (5/100).
- “Beaten down but solid” (South Korea): No. 8 of 22.
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−61.46% from the 52-week high
Analysts · 6 analysts
Average target₩358,333.34+112.41% vs. price
Buy 5 · Hold 1 · Sell 0 · Buy
TickerLandia Fingerprint: ALTEOGEN
Compared with similar companies: very weak momentum, very high profitability, and very high risk.
Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 1,069 Asia-Pacific stocks.
Pricevery high82
How much it costs relative to what it produces.
Metric Value Position in group Price/sales 48.2 85 EV/EBITDA 92.0 88 P/E (trailing 12 months) 97.1 83 Price/book 32.9 94 Forward P/E 32.0 61 Profitabilityvery high84
How much it earns on revenue and capital.
Metric Value Position in group Net margin 75.5% 99 Operating margin 47.2% 89 ROE 35.6% 83 ROA 11.2% 86 Gross margin 80.9% 61 Earnings stabilityaverage42
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 59.0% 41 Loss-making yearscounts in reverse: lower means more earnings stability 3 of 5 annual reports 43 Growthhigh61
How fast revenue and earnings are growing.
Metric Value Position in group Earnings growth (year over year) −168.10% 8 Revenue growth (year over year) +269.50% 92 Average revenue growth (3 years) +95.69% 83 Financial strengthhigh65
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Interest coverage 9.75 47 Debt/equitycounts in reverse: lower means more financial strength 0.01 86 Current ratio 5.73 68 Net debt/EBITDAcounts in reverse: lower means more financial strength · more cash than debt −0.54 59 Dividendvery low18
How much it returns to shareholders, and for how long.
Metric Value Position in group Payout ratio 10.9% 19 Consecutive dividend years 1 year 30 Dividend yield 0.2% 3 Market momentumvery weak5
How the stock has moved compared with the market.
Metric Value Position in group 1-year return −60.77% 1 Distance from 200-day average −36.91% 10 Riskvery high83
How much the price swings.
Metric Value Position in group Maximum drawdown (12 months) 60.8% 87 Volatility (60 days) 58.2% 79
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 18, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
ALTEOGEN is pricier than similar companies
ALTEOGEN's P/E (trailing 12 months): 97.1, +109% against the median of a group of 8 similar companies (46.5).
Compared with 8 similar companies
| Metric | ALTEOGEN | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 97.1 | High | |
| Forward P/E | 32.0 | Middle | |
| Operating margin | 47.2% | High | |
| ROE | 35.6% | High | |
| Debt/equity | 0.01 | Low |
Grey band: the middle half of the group; tick: the median; dot: ALTEOGEN. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
₩68.89B
Latest quarter · Q2 2026
Net income
₩28.42B
Latest quarter · Q2 2026
Quarterly net margin
41.2%
Latest quarter · Q2 2026
Numbers and valuation
Full valuation- Market cap
- ₩12.25T
- P/E
- 97.1
- EPS
- ₩2,610.42
- Volume
- 452.34K
- Daily trading
- €55.83M
- Dividend yield
- 0.17%
- Last ex-dividend on December 29, 2025
How ALTEOGEN is changing
All resultsRevenue grew 38.5% a year on average over the last 5 years
Operating margin rose from −102.0% to 49.5%
Free cash flow equal to 71% of net income
Returns
ALTEOGEN returns with dividends
₩1,000 invested in ALTEOGEN 5 years ago, on November 18, 2021, would be worth ₩3,814 today: +281.41% in total, +30.71% per year. This is the price return only: dividends are excluded.
| Period | ALTEOGEN | ₩1,000 becomes |
|---|---|---|
| 1 month | −29.41% | ₩706 |
| 6 months | −38.65% | ₩613 |
| Year to date | −51.21% | ₩488 |
| 1 year | −60.74% | ₩393 |
| 3 years | +222.99% | ₩3,230 |
| 5 years | +281.41% | ₩3,814 |
| 10 years | +4,977.27% | ₩50,773 |
From 1 year up with dividends reinvested, before taxes; under a year price only. Calculate your investment
The chart in detail
ALTEOGEN: technical analysis
ALTEOGEN is in a downtrend: the price is below its 50- and 200-session moving averages, and the 200-session average is falling. The price is 60.8% below its all-time closing high (₩430,000.00, November 18, 2025).
- Trend
- Downward
- RSI (14 sessions)
- 30
- Below 30: a strong fall in a short time
- vs 200-session average
- −36.91%
Active signals
RSI below 30: the stock has fallen a lot in a short time.
Support and resistance
Price areas where ALTEOGEN has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance₩253,205.13+50.09%3 touches, last on June 24, 2026
- Resistance₩244,935.90+45.19%3 touches, last on October 21, 2026
- Resistance₩207,000.00+22.70%2 touches, last on October 15, 2026
- Last price₩168,700.00
- No support below: the price is near the lows of the year
Volatility and risk
- Volatility (60 sessions, annualised)
- 58.2%
- Largest fall in the last year
- −60.84%
In session, November 18, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
ALTEOGEN: seasonality
Average monthly price change over 12 years
Over the last 12 years, the strongest month for ALTEOGEN has been February: +13.28% on average, positive in 8 years out of 12. The weakest has been January: −3.67% on average, positive in 5 years out of 12. November, the current month, has been positive in 8 years out of 11 (+7.92% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | −3.67% | −4.34% | 5 of 12 |
| February | +13.28% | +3.38% | 8 of 12 |
| March | +7.55% | +4.35% | 8 of 12 |
| April | +4.73% | +1.56% | 7 of 12 |
| May | +11.26% | −1.70% | 5 of 12 |
| June | +9.55% | +8.08% | 8 of 12 |
| July | +3.16% | −0.29% | 6 of 12 |
| August | +1.70% | +2.96% | 8 of 12 |
| September | +1.00% | −0.92% | 6 of 12 |
| October | −3.56% | −5.98% | 4 of 12 |
| November | +7.92% | +7.99% | 8 of 11 |
| December | +9.37% | +10.19% | 9 of 11 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
ALTEOGEN and its competitors
ALT-P1, a long-acting human growth hormone in a Phase IIa trial, and ALT-Q2, a coagulation factor VII product for hemophilia, anchor the development pipeline of ALTEOGEN Inc. Its oncology candidates include ALT-P7, a targeted drug for breast and gastric cancer in Phase I, and ALT-Q5, an antibody-drug conjugate for ovarian cancer built on its NexMab ADC technology.
- Headquarters
- Daejeon, South Korea
- Employees
- 181
- Founded
- 2008
- Chief executive
- Soon-Jae Park
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| ALTEOGEN196170 | $9.17B | 47.2% | 97.1 | −38.65% |
| Genscript Biotech1548 | $8.83B | 14.9% | — | +111.76% |
| Haisco Pharmaceutical Group002653 | $9.79B | 21.1% | 50.6 | +4.89% |
| Akeso9926 | $7.6B | -30.7% | — | −48.20% |
| Pharmaron Beijing300759 | $11.45B | 14.0% | 42.4 | +49.16% |
| Sino Biopharmaceutical1177 | $12.49B | 28.2% | 36.7 | +0.57% |
Same industry or related industries, similar size. Compare ALTEOGEN with its competitors · Full profile
